The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial
Open accessAbstract
Importance: After percutaneous coronary intervention (PCI), patients with CYP2C19*2 or *3 loss-of-function (LOF) variants treated with clopidogrel have increased risk of ischemic events. Whether genotype-guided selection of oral P2Y12 inhibitor therapy improves ischemic outcomes is unknown. Objective: To determine the effect of a genotype-guided oral P2Y12 inhibitor strategy on ischemic outcomes in CYP2C19 LOF carriers after PCI. Design, Setting, and Participants: Open-label randomized clinical trial of 5302 patients undergoing PCI for acute coronary syndromes (ACS) or stable coronary artery disease (CAD). Patients were enrolled at 40 centers in the US, Canada, South Korea, and Mexico from May 2013 through October 2018; final date of follow-up was October 2019. Interventions: Patients randomized to the genotype-guided group (n = 2652) underwent point-of-care genotyping. CYP2C19 LOF carriers were prescribed ticagrelor and noncarriers clopidogrel. Patients randomized to the conventional group (n = 2650) were prescribed clopidogrel and underwent genotyping after 12 months. Main Outcomes and Measures: The primary end point was a composite of cardiovascular death, myocardial infarction, stroke, stent thrombosis, and severe recurrent ischemia at 12 months. A secondary end point was major or minor bleeding at 12 months. The primary analysis was in patients with CYP2C19 LOF variants, and secondary analysis included all randomized patients. The trial had 85% power to detect a minimum hazard ratio of 0.50. Results: Among 5302 patients randomized (median age, 62 years; 25% women), 82% had ACS and 18% had stable CAD; 94% completed the trial. Of 1849 with CYP2C19 LOF variants, 764 of 903 (85%) assigned to genotype-guided therapy received ticagrelor, and 932 of 946 (99%) assigned to conventional therapy received clopidogrel. The primary end point occurred in 35 of 903 CYP2C19 LOF carriers (4.0%) in the genotype-guided therapy group and 54 of 946 (5.9%) in the conventional therapy group at 12 months (hazard ratio [HR], 0.66 [95% CI, 0.43-1.02]; P = .06). None of the 11 prespecified secondary end points showed significant differences, including major or minor bleeding in CYP2C19 LOF carriers in the genotype-guided group (1.9%) vs the conventional therapy group (1.6%) at 12 months (HR, 1.22 [95% CI, 0.60-2.51]; P = .58). Among all randomized patients, the primary end point occurred in 113 of 2641 (4.4%) in the genotype-guided group and 135 of 2635 (5.3%) in the conventional group (HR, 0.84 [95% CI, 0.65-1.07]; P = .16). Conclusions and Relevance: Among CYP2C19 LOF carriers with ACS and stable CAD undergoing PCI, genotype-guided selection of an oral P2Y12 inhibitor, compared with conventional clopidogrel therapy without point-of-care genotyping, resulted in no statistically significant difference in a composite end point of cardiovascular death, myocardial infarction, stroke, stent thrombosis, and severe recurrent ischemia based on the prespecified analysis plan and the treatment effect that the study was powered to detect at 12 months. Trial Registration: ClinicalTrials.gov Identifier: NCT01742117.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
Mega, J. L., Close, S. L., Wiviott, S. D., Shen, L., Hockett, R. D., Brandt, J. T., Walker, J. R., Antman, E. M., Macias, W., Braunwald, E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809171 · Cited by 2,497
Chesebro, J. H., Knatterud, G., Roberts, R., Borer, J., Cohen, L. S., Dalen, J., Dodge, H. T., Francis, C. K., Hillis, D., & Ludbrook, P. (1987) · Circulation · doi:10.1161/01.cir.76.1.142 · Cited by 2,244
Mega, J. L., Simon, T., Collet, J.-P., Anderson, J. L., Antman, E. M., Bliden, K., Cannon, C. P., Danchin, N., Giusti, B., Gurbel, P., et al. (2010) · JAMA · doi:10.1001/jama.2010.1543 · Cited by 1,135
A Genotype-Guided Strategy for Oral P2Y 12 Inhibitors in Primary PCI
Claassens, D. M. F., Vos, G. J. A., Bergmeijer, T. O., Hermanides, R. S., van ’t Hof, A. W. J., van der Harst, P., Barbato, E., Morisco, C., Tjon Joe Gin, R. M., Asselbergs, F. W., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907096 · Cited by 654
Repeated assessment of results in clinical trials of cancer treatment
Haybittle, J. L. (1971) · The British Journal of Radiology · doi:10.1259/0007-1285-44-526-793 · Cited by 517
Roberts, J. D., Wells, G. A., Le May, M. R., Labinaz, M., Glover, C., Froeschl, M., Dick, A., Marquis, J.-F., O'Brien, E., Goncalves, S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60161-5 · Cited by 391
Self-citationClopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study
Pereira, N. L., Rihal, C. S., So, D. Y. F., Rosenberg, Y., Lennon, R. J., Mathew, V., Goodman, S. G., Weinshilboum, R. M., Wang, L., Baudhuin, L. M., et al. (2019) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.119.007811 · Cited by 227
Self-citationWriting Committee Members, Holmes, D. R., Dehmer, G. J., Kaul, S., Leifer, D., O'Gara, P. T., & Stein, C. M. (2010) · Circulation · doi:10.1161/cir.0b013e3181ee08ed · Cited by 223
Cited by
2024 ESC Guidelines for the management of chronic coronary syndromes
Vrints, C., Andreotti, F., Koskinas, K. C., Rossello, X., Adamo, M., Ainslie, J., Banning, A. P., Budaj, A., Buechel, R. R., Chiariello, G. A., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae177 · Cited by 2,774
Swen, J. J., van der Wouden, C. H., Manson, L. E., Abdullah-Koolmees, H., Blagec, K., Blagus, T., Böhringer, S., Cambon-Thomsen, A., Cecchin, E., Cheung, K.-C., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)01841-4 · Cited by 556
Bergmark, B. A., Mathenge, N., Merlini, P. A., Lawrence-Wright, M. B., & Giugliano, R. P. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02391-6 · Cited by 445
Ticagrelor versus Clopidogrel in CYP2C19 Loss-of-Function Carriers with Stroke or TIA
Wang, Y., Meng, X., Wang, A., Xie, X., Pan, Y., Johnston, S. C., Li, H., Bath, P. M., Dong, Q., Xu, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2111749 · Cited by 395
Self-citationKim, H. K., Tantry, U. S., Smith, S. C., Jeong, M. H., Park, S.-J., Kim, M. H., Lim, D.-S., Shin, E.-S., Park, D.-W., Huo, Y., et al. (2021) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1718729 · Cited by 345
Self-citation
Metadata
- Authors
- Pereira, N. L., Farkouh, M. E., So, D., Lennon, R., Geller, N., Mathew, V., Bell, M., Bae, J.-H., Jeong, M. H., Chavez, I., Gordon, P., Abbott, J. D., Cagin, C., Baudhuin, L., Fu, Y.-P., Goodman, S. G., Hasan, A., Iturriaga, E., Lerman, A., Sidhu, M., Tanguay, J.-F., Wang, L., Weinshilboum, R., Welsh, R., Rosenberg, Y., Bailey, K., & Rihal, C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2020-08-25
- Volume
- 324
- Issue
- 8
- Pages
- 761
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W3080963011
- Cited by
- 424
- References
- 18
- FWCI
- 36.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2020.12443
- The paper
- Pereira, N. L., Farkouh, M. E., So, D., Lennon, R., Geller, N., Mathew, V., Bell, M., Bae, J.-H., Jeong, M. H., Chavez, I., Gordon, P., Abbott, J. D., Cagin, C., Baudhuin, L., Fu, Y.-P., Goodman, S. G., Hasan, A., Iturriaga, E., Lerman, A., . . . Rihal, C. (2020). Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2020.12443
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.